^
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
CMG901 Sensitive: B - Late Trials
Keymed Biosci Press Release - 3 weeks (NewB)
|
CMG901 Sensitive: B - Late Trials
Keymed Biosci Press Release - 3 weeks - (New B)
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
trastuzumab Sensitive: A1 - Approval
ISPOR 2022 - 3 weeks (NewA1)
|
trastuzumab Sensitive: A1 - Approval
ISPOR 2022 - 3 weeks - (New C3)
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
|
cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
|
fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
TPF Sensitive: A1 - Approval
|
TPF Sensitive: A1 - Approval
|
HER-2 negative + PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 negative + PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
HER-2 negative + PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 negative + PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
trifluridine/tipiracil Sensitive: A1 - Approval
|
trifluridine / tipiracil Sensitive: A1 - Approval
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
ramucirumab Sensitive: A1 - Approval
|
ramucirumab Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
trastuzumab Sensitive: A1 - Approval
|
trastuzumab Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab + trastuzumab Sensitive: A1 - Approval
|
pembrolizumab + trastuzumab Sensitive: A1 - Approval
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
disitamab vedotin Sensitive: A1 - Approval
|
disitamab vedotin Sensitive: A1 - Approval
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
cisplatin + capecitabine Sensitive: A2 - Guideline
|
cisplatin + capecitabine Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
DOF Sensitive: A2 - Guideline
|
DOF Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
TCF Sensitive: A2 - Guideline
|
TCF Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
FP Sensitive: A2 - Guideline
|
FP Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
CaT Sensitive: A2 - Guideline
|
CaT Sensitive: A2 - Guideline
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
CAPOX Sensitive: A2 - Guideline
|
CAPOX Sensitive: A2 - Guideline
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
|
5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
FP Sensitive: A2 - Guideline
|
FP Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
capecitabine Sensitive: A2 - Guideline
|
capecitabine Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
5-fluorouracil Sensitive: A2 - Guideline
|
5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
DP Sensitive: A2 - Guideline
|
DP Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
FLOT Sensitive: A2 - Guideline
|
FLOT Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Gastroesophageal Junction Adenocarcinoma
|
MSI-H/dMMR
|
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
cisplatin + capecitabine Sensitive: A2 - Guideline
|
cisplatin + capecitabine Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
5-fluorouracil + irinotecan Sensitive: A2 - Guideline
|
5-fluorouracil + irinotecan Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
irinotecan Sensitive: A2 - Guideline
|
irinotecan Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
docetaxel Sensitive: A2 - Guideline
|
docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
docetaxel + irinotecan Sensitive: A2 - Guideline
|
docetaxel + irinotecan Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
IP Sensitive: A2 - Guideline
|
IP Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
|
5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
capecitabine + oxaliplatin Sensitive: A2 - Guideline
|
capecitabine + oxaliplatin Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Gastroesophageal Junction Adenocarcinoma
|
NTRK3 fusion
|
Gastroesophageal Junction Adenocarcinoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Gastroesophageal Junction Adenocarcinoma
|
NTRK2 fusion
|
Gastroesophageal Junction Adenocarcinoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Gastroesophageal Junction Adenocarcinoma
|
NTRK1 fusion
|
Gastroesophageal Junction Adenocarcinoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Gastroesophageal Junction Adenocarcinoma
|
NTRK3 fusion
|
Gastroesophageal Junction Adenocarcinoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Gastroesophageal Junction Adenocarcinoma
|
NTRK2 fusion
|
Gastroesophageal Junction Adenocarcinoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Gastroesophageal Junction Adenocarcinoma
|
NTRK1 fusion
|
Gastroesophageal Junction Adenocarcinoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER2 inhibitor Sensitive: A2 - Guideline
|
HER2 inhibitor Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
oxaliplatin Sensitive: A2 - Guideline
|
oxaliplatin Sensitive: A2 - Guideline
|
TMB-H
|
Gastroesophageal Junction Adenocarcinoma
|
TMB-H
|
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
paclitaxel + 5-fluorouracil Sensitive: A2 - Guideline
|
paclitaxel + 5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
paclitaxel + capecitabine Sensitive: A2 - Guideline
|
paclitaxel + capecitabine Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
FOLFOX Sensitive: A2 - Guideline
|
FOLFOX Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
carboplatin + 5-fluorouracil + docetaxel Sensitive: A2 - Guideline
|
carboplatin + 5-fluorouracil + docetaxel Sensitive: A2 - Guideline
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
|
fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab + trastuzumab Sensitive: A2 - Guideline
|
pembrolizumab + trastuzumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Gastroesophageal Junction Adenocarcinoma
|
MSI-H/dMMR
|
Gastroesophageal Junction Adenocarcinoma
|
dostarlimab Sensitive: A2 - Guideline
|
dostarlimab Sensitive: A2 - Guideline
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
trastuzumab + pertuzumab Sensitive: B - Late Trials
|
trastuzumab + pertuzumab Sensitive: B - Late Trials
|
FGFR2b overexpression + HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
FGFR2b overexpression + HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
AMG 552 Sensitive: B - Late Trials
|
AMG 552 Sensitive: B - Late Trials
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
nivolumab Sensitive: B - Late Trials
|
nivolumab Sensitive: B - Late Trials
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab Sensitive: B - Late Trials
|
pembrolizumab Sensitive: B - Late Trials
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
Immunotherapy Sensitive: B - Late Trials
|
Immunotherapy Sensitive: B - Late Trials
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
nivolumab Sensitive: B - Late Trials
|
nivolumab Sensitive: B - Late Trials
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
avelumab Resistant: B - Late Trials
|
avelumab Resistant: B - Late Trials
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
ramucirumab Sensitive: B - Late Trials
|
ramucirumab Sensitive: B - Late Trials
|
MET expression
|
Gastroesophageal Junction Adenocarcinoma
|
MET expression
|
Gastroesophageal Junction Adenocarcinoma
|
AMG 102 Resistant: B - Late Trials
|
AMG 102 Resistant: B - Late Trials
|
MET amplification
|
Gastroesophageal Junction Adenocarcinoma
|
MET amplification
|
Gastroesophageal Junction Adenocarcinoma
|
AMG 102 Resistant: B - Late Trials
|
AMG 102 Resistant: B - Late Trials
|
HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
|
trastuzumab Sensitive: B - Late Trials
|
trastuzumab Sensitive: B - Late Trials
|
DKK1 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
DKK1 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
DKN-01 Sensitive: B - Late Trials
|
DKN-01 Sensitive: B - Late Trials
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
sintilimab Sensitive: B - Late Trials
|
sintilimab Sensitive: B - Late Trials
|
PD-L1 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
PD-L1 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab Sensitive: B - Late Trials
|
pembrolizumab Sensitive: B - Late Trials
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
ramucirumab Sensitive: B - Late Trials
|
ramucirumab Sensitive: B - Late Trials
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
CYNK-101 Sensitive: B - Late Trials
|
CYNK-101 Sensitive: B - Late Trials
|
PD-L1 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
PD-L1 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
nivolumab Sensitive: B - Late Trials
|
nivolumab Sensitive: B - Late Trials
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
tislelizumab Sensitive: B - Late Trials
|
tislelizumab Sensitive: B - Late Trials
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
nivolumab + ipilimumab Sensitive: C1 - Off-label
|
nivolumab + ipilimumab Sensitive: C1 - Off-label
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
durvalumab Resistant: C1 - Off-label
|
durvalumab Resistant: C1 - Off-label
|
MSI-H/dMMR
|
Gastroesophageal Junction Adenocarcinoma
|
MSI-H/dMMR
|
Gastroesophageal Junction Adenocarcinoma
|
tislelizumab Sensitive: C1 - Off-label
|
tislelizumab Sensitive: C1 - Off-label
|
HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab + trastuzumab Sensitive: C2 – Inclusion Criteria
|
pembrolizumab + trastuzumab Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
paclitaxel Sensitive: C2 – Inclusion Criteria
|
paclitaxel Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
PRS-343 Sensitive: C2 – Inclusion Criteria
|
PRS-343 Sensitive: C2 – Inclusion Criteria
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
rivoceranib Sensitive: C2 – Inclusion Criteria
|
rivoceranib Sensitive: C2 – Inclusion Criteria
|
HER-2 underexpression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 underexpression
|
Gastroesophageal Junction Adenocarcinoma
|
fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria
|
fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria
|
HER-2 expression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 expression
|
Gastroesophageal Junction Adenocarcinoma
|
fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria
|
fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria
|
HER-2 mutation
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 mutation
|
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab + margetuximab Sensitive: C2 – Inclusion Criteria
|
pembrolizumab + margetuximab Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
|
fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria
|
fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
|
ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria
|
ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria
|
CLDN18.2 expression
|
Gastroesophageal Junction Adenocarcinoma
|
CLDN18.2 expression
|
Gastroesophageal Junction Adenocarcinoma
|
IMAB362 Sensitive: C2 – Inclusion Criteria
|
IMAB362 Sensitive: C2 – Inclusion Criteria
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
camrelizumab Sensitive: C2 – Inclusion Criteria
|
camrelizumab Sensitive: C2 – Inclusion Criteria
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria
|
camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria
|
